Crossmark

Emerging Therapies and Novel Targets for TDP-43 Proteinopathy in ALS/FTD

Crossref DOI link: https://doi.org/10.1007/s13311-022-01260-5

Published Print: 2022-07

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Hayes, Lindsey R. https://orcid.org/0000-0003-4818-6054
Kalab, Petr
Funding

Funding for this research was provided by:

National Institute of Neurological Disorders and Stroke (K08NS104273)

National Institute of Neurological Disorders and Stroke (R01NS123538)

National Institute of Neurological Disorders and Stroke (R03NS127011)

Robert Packard Center for ALS Research, Johns Hopkins University (N/A)
License Information

Text and Data Mining valid from 2022-07-01

Text and Data Mining valid from 2022-07-01

Version of Record valid from 2023-08-18
More Information

This article is maintained by: Elsevier

Article Title: Emerging Therapies and Novel Targets for TDP-43 Proteinopathy in ALS/FTD

Journal Title: Neurotherapeutics

CrossRef DOI link to publisher maintained version: https://doi.org/10.1007/s13311-022-01260-5

Content Type: article

Copyright: Copyright © 2022 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.